Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective an...

Descripción completa

Detalles Bibliográficos
Autores principales: Burdge, Gemma, Hardman, Alice, Carbery, Isabel, Broglio, Giacomo, Greer, Dan, Selinger, Christian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571673/
https://www.ncbi.nlm.nih.gov/pubmed/36233537
http://dx.doi.org/10.3390/jcm11195669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571673/
https://www.ncbi.nlm.nih.gov/pubmed/36233537
http://dx.doi.org/10.3390/jcm11195669

Ejemplares similares